Irreversible Electroporation(IRE) For Unresectable Renal Tumors

  • End date
    Jan 1, 2025
  • participants needed
  • sponsor
    Fuda Cancer Hospital, Guangzhou
Updated on 24 January 2021
renal neoplasm


The purpose of this study is to investigate the safety and efficacy of irreversible electroporation (IRE) for unresectable renal tumors.


By enrolling patients with renal tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for renal tumors .

Condition Malignant neoplasm of kidney, Kidney Cancer, Renal Cancer, kidney tumor, renal tumors, neoplasia renal, renal neoplasm, renal tumor, kidney tumours, kidney tumors
Treatment Irreversible Electroporation
Clinical Study IdentifierNCT02335827
SponsorFuda Cancer Hospital, Guangzhou
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 80 yrs?
Gender: Male or Female
Do you have any of these conditions: Renal Cancer or Kidney Cancer or Malignant neoplasm of kidney?
Do you have any of these conditions: Malignant neoplasm of kidney or renal tumor or kidney tumor or Renal Cancer or kidney tumors or kidney tumours or Kidney Cancer or neoplasia renal or ...?
an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73 m2
QT-interval >550 ms or cardiac arrhythmias or condition after myocardial infarction, that make an ECG-synchronisation unfeasible
active infection or severe health interference, that make taking part in a study unfeasible
pregnancy, lactation period
general contraindications for anesthesia, endotracheal anesthesia and muscle relaxation
psychiatric disorders that make taking part in a study or giving informed consent unfeasible
haemorrhage, impossible intermission of taking blood thinner, untreatable thrombophilia
thromboplastin time 50 %, thrombocytes 50 Gpt/L; partial thromboplastin time >50
untreated urinary retention
severe hepatic dysfunction
any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigator's assessment)
taking part in another clinical study for renal tumor
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note